BRPI0915915A2 - vacinas para hiv com base na marcação de gag e nef maximizada para células dendríticas - Google Patents

vacinas para hiv com base na marcação de gag e nef maximizada para células dendríticas

Info

Publication number
BRPI0915915A2
BRPI0915915A2 BRPI0915915A BRPI0915915A BRPI0915915A2 BR PI0915915 A2 BRPI0915915 A2 BR PI0915915A2 BR PI0915915 A BRPI0915915 A BR PI0915915A BR PI0915915 A BRPI0915915 A BR PI0915915A BR PI0915915 A2 BRPI0915915 A2 BR PI0915915A2
Authority
BR
Brazil
Prior art keywords
nef
labeling
dendritic cells
vaccines based
hiv vaccines
Prior art date
Application number
BRPI0915915A
Other languages
English (en)
Portuguese (pt)
Inventor
Cobb Amanda
Flamar Anne-Laure
Zurawski Gerard
Mead Holly
F Banchereau Jacques
Montes Monica
Original Assignee
Baylor Res Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Res Institute filed Critical Baylor Res Institute
Publication of BRPI0915915A2 publication Critical patent/BRPI0915915A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0915915A 2008-07-16 2009-07-16 vacinas para hiv com base na marcação de gag e nef maximizada para células dendríticas BRPI0915915A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8123408P 2008-07-16 2008-07-16
PCT/US2009/050903 WO2010009346A2 (en) 2008-07-16 2009-07-16 Hiv vaccine based on targeting maximized gag and nef to dendritic cells

Publications (1)

Publication Number Publication Date
BRPI0915915A2 true BRPI0915915A2 (pt) 2019-09-24

Family

ID=41551022

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915915A BRPI0915915A2 (pt) 2008-07-16 2009-07-16 vacinas para hiv com base na marcação de gag e nef maximizada para células dendríticas

Country Status (19)

Country Link
US (1) US9109011B2 (cg-RX-API-DMAC7.html)
EP (3) EP2966091B1 (cg-RX-API-DMAC7.html)
JP (2) JP5984388B2 (cg-RX-API-DMAC7.html)
KR (2) KR101548143B1 (cg-RX-API-DMAC7.html)
CN (1) CN102625714B (cg-RX-API-DMAC7.html)
AP (1) AP2011005541A0 (cg-RX-API-DMAC7.html)
AU (1) AU2009270771B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0915915A2 (cg-RX-API-DMAC7.html)
CA (1) CA2730742C (cg-RX-API-DMAC7.html)
DK (1) DK2966091T3 (cg-RX-API-DMAC7.html)
ES (2) ES2685823T3 (cg-RX-API-DMAC7.html)
IL (1) IL210646A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011000507A (cg-RX-API-DMAC7.html)
MY (1) MY155377A (cg-RX-API-DMAC7.html)
NZ (3) NZ596171A (cg-RX-API-DMAC7.html)
PT (1) PT2966091T (cg-RX-API-DMAC7.html)
RU (2) RU2539765C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010009346A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201100398B (cg-RX-API-DMAC7.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010009346A2 (en) * 2008-07-16 2010-01-21 Baylor Research Institute Hiv vaccine based on targeting maximized gag and nef to dendritic cells
JP2012501323A (ja) * 2008-08-29 2012-01-19 アカデミシュ ジーケンハウス ライデン ハー．オー．デー．エン． ルムク 対象の腫瘍流入領域リンパ節へのｃｄ４０アゴニストの送達
CN108373509A (zh) 2009-03-10 2018-08-07 贝勒研究院 靶向抗原呈递细胞的抗病毒疫苗
JP5883653B2 (ja) * 2009-03-10 2016-03-15 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 抗原提示細胞ターゲティング抗ウイルスワクチン
CA2754862C (en) 2009-03-10 2019-04-02 Baylor Research Institute Anti-cd40 antibodies and uses thereof
AU2010291939B2 (en) * 2009-09-14 2012-11-15 Baylor Research Institute Vaccines directed to Langerhans cells
JP5628544B2 (ja) * 2010-04-07 2014-11-19 株式会社豊田中央研究所 クロストリジウム・サーモセラム由来のタンパク質複合体を構築するためのタンパク質及びその利用
CA2798616A1 (en) 2010-05-07 2011-11-10 Baylor Research Institute Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells
CN103328005A (zh) * 2010-08-13 2013-09-25 贝勒研究院 基于将到抗体的佐剂直接靶向抗原呈递细胞的新型疫苗佐剂
US20120128710A1 (en) * 2010-11-02 2012-05-24 Baylor Research Institute Enhancement of Pathogen-Specific Memory Th17 Cell Responses
WO2012122396A1 (en) * 2011-03-08 2012-09-13 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
TW201300418A (zh) * 2011-03-25 2013-01-01 Baylor Res Inst 用於抗ｃ型肝炎病毒免疫之組合物及方法
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
WO2014031984A1 (en) * 2012-08-24 2014-02-27 Baylor Research Institute Immunological detection methods and compositions
WO2014039840A1 (en) * 2012-09-07 2014-03-13 Baylor Research Institute Hiv vaccine compositions and methods
KR102270618B1 (ko) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
US20160296609A1 (en) 2013-06-28 2016-10-13 Baylor Research Institute Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis
US10286058B2 (en) 2014-01-13 2019-05-14 Baylor Research Institute Vaccines against HPV and HPV-related diseases
TWI733652B (zh) 2014-07-11 2021-07-21 美商基利科學股份有限公司 用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑
CN105821030A (zh) * 2015-01-04 2016-08-03 彭霞 表达α1，3半乳糖转移酶的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法
CN105821029A (zh) * 2015-01-04 2016-08-03 彭霞 异源融合基因修饰的癌细胞/树突状细胞融合肿瘤疫苗及其制备方法
US20180356398A1 (en) 2017-06-09 2018-12-13 Fujifilm Corporation Living tissue model device, vascular wall model, vascular wall model device and method of evaluating test substance
JP7693189B2 (ja) 2017-08-10 2025-06-17 グッド ティー セルズ、 インコーポレイテッド 癌治療のためのｔ細胞の活性化方法
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
US20210251994A1 (en) 2018-06-15 2021-08-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
CN113597430A (zh) 2019-02-08 2021-11-02 古德T细胞有限公司 激活t细胞用于癌症治疗的方法
KR20220004985A (ko) 2019-03-27 2022-01-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Cd40 활성화 특성을 가진 재조합 단백질
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
CA3161633A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines
KR20220131895A (ko) * 2019-11-21 2022-09-29 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-pd-1/il-15 면역사이토카인을 이용하여 pd-1을 표적으로 하는 신규한 면역요법
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CA3184802A1 (en) 2020-05-26 2021-12-02 Inserm (Institut National De La Sante Et De La Recherche Medicale) Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
US20240010739A1 (en) 2020-11-12 2024-01-11 Institut National De La Santé Et De La Recherche Médicale (Inserm) Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes
GB202019879D0 (en) * 2020-12-16 2021-01-27 Ucl Business Ltd Polypeptide
KR20230124672A (ko) 2020-12-23 2023-08-25 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항원 제시 세포에 대한 momp vs4 항원의 표적화에 기반한클라미디아 백신
MX2023008986A (es) 2021-01-29 2023-08-15 Inst Nat Sante Rech Med Polipeptidos antigenicos de chlamydia trachomatis y usos de los mismos con fines de vacuna.
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
EP4363059A1 (en) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
MX2024006003A (es) 2021-11-17 2024-08-06 Inst Nat Sante Rech Med Vacunas universales contra el sarbecovirus.
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
KR20250080855A (ko) 2022-10-05 2025-06-05 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 니파바이러스 감염에 대한 dc 표적 백신
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3949064A (en) 1973-10-26 1976-04-06 Baxter Laboratories, Inc. Method of detecting antigens or antibodies
US4174384A (en) 1975-06-30 1979-11-13 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
DK8189A (da) 1988-01-12 1989-07-13 Bunge Australia Antigen-antistof-konjugater, deres fremstilling og anvendelse
US6054312A (en) * 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
AU7275698A (en) * 1998-05-01 1999-11-23 Procter & Gamble Company, The Laundry detergent and/or fabric care compositions comprising a modified antimicrobial protein
WO2000000156A2 (en) * 1998-06-26 2000-01-06 Trustees Of Dartmouth College Methods for modulating immunological responses by targeting antigen to apcs in conjuction with anti-cd40 ligands
JP2000157282A (ja) * 1998-11-30 2000-06-13 Toyota Central Res & Dev Lab Inc 酵素配列複合体及び固定化酵素配列複合体とそれらの製造方法、担体分子及び酵素
BR0109455A (pt) * 2000-03-23 2003-06-03 Akzo Nobel Nv Uso de mia e/ou seus fragmentos, método para tratar mamìferos sofrendo de, ou susceptìvel a, uma doença inflamatória, peptìdeo, composição farmacêutica, e, uso dos peptìdeos
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
AU2002305452A1 (en) 2001-05-08 2002-11-18 Emory University Regulating immine responses using dendritic cells
GB0118367D0 (en) 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
RU2312896C2 (ru) * 2001-09-20 2007-12-20 Глаксо Груп Лимитед Последовательность нуклеиновой кислоты, кодирующая белок gag вич-1, способ получения указанной последовательности, вектор, содержащий ее, белок, кодируемый ею, фармацевтическая композиция и их применение для профилактики и/или лечения вич-инфекции и спида
WO2003033695A1 (fr) 2001-10-11 2003-04-24 Katakura Industries Co., Ltd. Procede de purification de proteine fusionnee recombinee et procede de production de proteine utilisant ledit procede de purification
CA2468878A1 (en) * 2001-11-30 2003-06-05 Crucell Holland B.V. Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their productionor generation
EP2258712A3 (en) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
JP2004236504A (ja) * 2003-02-03 2004-08-26 Toyota Central Res & Dev Lab Inc 酵素配列複合体及び固定化酵素配列複合体とそれらの製造方法、担体分子及び酵素
JP2005143444A (ja) 2003-11-19 2005-06-09 Lion Corp キメラ酵素及び洗浄剤組成物
PT1771474E (pt) * 2004-07-20 2010-05-03 Genentech Inc Inibidores de proteína 4 do tipo angiopoietina, combinações e sua utilização
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
US20080063656A1 (en) 2004-08-09 2008-03-13 Emini Emilio A Adenoviral Vector Compositions
MX2007005256A (es) * 2004-11-16 2008-03-11 Crucell Holland Bv Vacunas multivalentes que comprenden vectores virales recombinantes.
EP1752533A1 (en) 2005-08-12 2007-02-14 Institut National de la Recherche Agronomique Fusion proteins between plant cell-wall degrading enzymes, and their uses
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
WO2010009346A2 (en) * 2008-07-16 2010-01-21 Baylor Research Institute Hiv vaccine based on targeting maximized gag and nef to dendritic cells

Also Published As

Publication number Publication date
JP5984388B2 (ja) 2016-09-06
RU2539765C2 (ru) 2015-01-27
MX2011000507A (es) 2011-05-24
AP2011005541A0 (en) 2011-02-28
CA2730742C (en) 2017-05-23
PT2966091T (pt) 2018-07-26
EP3388450B1 (en) 2021-07-07
EP2966091A1 (en) 2016-01-13
CA2730742A1 (en) 2010-01-21
EP2966091B1 (en) 2018-04-25
WO2010009346A8 (en) 2010-08-19
EP2307048A2 (en) 2011-04-13
KR101548143B1 (ko) 2015-08-28
AU2009270771A1 (en) 2010-01-21
ES2685823T3 (es) 2018-10-11
EP2307048A4 (en) 2012-02-29
MY155377A (en) 2015-10-15
AU2009270771B2 (en) 2012-08-23
RU2012153053A (ru) 2014-06-20
NZ596171A (en) 2012-05-25
JP6109800B2 (ja) 2017-04-05
RU2011105119A (ru) 2012-08-27
WO2010009346A3 (en) 2010-04-29
KR20110036618A (ko) 2011-04-07
NZ590628A (en) 2012-03-30
IL210646A0 (en) 2011-03-31
JP2011528233A (ja) 2011-11-17
US20100135994A1 (en) 2010-06-03
ES2890230T3 (es) 2022-01-18
CN102625714A (zh) 2012-08-01
NZ594540A (en) 2012-01-12
DK2966091T3 (en) 2018-07-30
US9109011B2 (en) 2015-08-18
JP2015071598A (ja) 2015-04-16
WO2010009346A2 (en) 2010-01-21
CN102625714B (zh) 2015-08-19
ZA201100398B (en) 2011-10-26
KR20130081721A (ko) 2013-07-17
EP3388450A1 (en) 2018-10-17

Similar Documents

Publication Publication Date Title
BRPI0915915A2 (pt) vacinas para hiv com base na marcação de gag e nef maximizada para células dendríticas
BRPI1014886A2 (pt) "adesivos com base em polímero híbrido acrílico de silicone.'
BRPI0821236A2 (pt) perfurador com duas pontas
EP2572329A4 (en) E-MAIL TAGS
DK3335728T3 (da) Biokemisk stabiliseret hiv-1 env-trimervaccine
PT2461973E (pt) Módulos fotovoltaicos com placa posterior à base de polipropileno
IL258409A (en) Laser daylight designation and pointing
EP2424791A4 (en) CUP HOLDERS OF USE
JP2011510006A5 (cg-RX-API-DMAC7.html)
AR072161A1 (es) Composicion con gradiente de grasas
BRPI0818354A2 (pt) vacina preventiva do hiv baseada em anticorpos específicos para o hiv
BRPI0908119A2 (pt) publicidade com base na localização do automóvel
BRPI0922060A2 (pt) liga á base de níquel formadora de óxido de alumínio.
FI20085762L (fi) Alusterä
CL2010000093S1 (es) Grifo con dos manillas de control que presenta una porción central formada por una base prismática de base rectangular, sobre la cual sobresale un prisma central de base rectangular, cuyo extremo superior presenta un quiebre en ángulo agudo de vértice redondeado y dirigido hacia adelante, ambos costados se sitúan las manillas.
BRPI0909784A2 (pt) cátodos para baterias de tamanho aa e aaa
RU2009107569A (ru) 1-гексадецил-5-(1-пиренбутил)-n-(l-орнитил)-l-глутамат
HK1155065A (en) Hiv vaccine based on targeting maximized gag and nef to dendritic cells
RU2009149491A (ru) 2,3-дихлор-4-[(6-хлор-5-циано-4-метилпиридил-2)-метилгидразоно]-бутен-2-овая кислота в качестве антидота 2,4-д на подсолнечнике
EP2501717A4 (en) ADVANCED MALARIA MSP-1 SUB-UNIT VACCINE
BRPI0815743A2 (pt) Proteínas hiv env com modificações no laço v3
EP2242110A4 (en) SOLAR BATTERY BASE
BRPI0915505A8 (pt) tratamento de mensagens
AU324840S (en) Document holder
RU2010154742A (ru) N-изопропиламида 2-(6,7-диметокси-3-спиро-циклопентил-3,4-дигидроизохинолил-1)-этановой кислоты гидрохлорид, обладающий гипертензивной активностью

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.